CACNG5

Summary

CACNG5 (calcium voltage-gated channel auxiliary subunit gamma 5, HGNC:1409) is a protein-coding gene on chromosome 17q24.2, encoding Voltage-dependent calcium channel gamma-5 subunit (Q9UF02). Regulates the gating properties of AMPA-selective glutamate receptors (AMPARs).

The protein encoded by this gene is a type II transmembrane AMPA receptor regulatory protein (TARP). TARPs regulate both trafficking and channel gating of the AMPA receptors. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members, a type I TARP and a calcium channel gamma subunit. This gene is a susceptibility locus for schizophrenia and bipolar disorder.

Source: NCBI Gene 27091 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 51 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_145811

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1409
Approved symbol	CACNG5
Name	calcium voltage-gated channel auxiliary subunit gamma 5
Location	17q24.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000075429
Ensembl biotype	protein_coding
OMIM	606405
Entrez	27091

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000307139, ENST00000533854, ENST00000673855

RefSeq mRNA: 2 — MANE Select: NM_145811 NM_001371476, NM_145811

CCDS: CCDS11665, CCDS92382

Canonical transcript exons

ENST00000533854 — 6 exons

Exon	Start	End
ENSE00000406082	66878972	66879058
ENSE00000742698	66884516	66884661
ENSE00002142694	66884983	66894751
ENSE00002148235	66835117	66835250
ENSE00002200600	66877230	66877528
ENSE00002472944	66880557	66880697

Expression profiles

Bgee: expression breadth broad, 46 present calls, max score 66.84.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3061 / max 58.0704, expressed in 107 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
162318	0.3061	107

Top tissues by expression

233 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	66.84	silver quality
anterior cingulate cortex	UBERON:0009835	65.21	gold quality
Brodmann (1909) area 9	UBERON:0013540	64.15	gold quality
prefrontal cortex	UBERON:0000451	63.76	gold quality
islet of Langerhans	UBERON:0000006	63.69	gold quality
putamen	UBERON:0001874	63.67	gold quality
ganglionic eminence	UBERON:0004023	63.02	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	62.91	gold quality
nucleus accumbens	UBERON:0001882	62.86	gold quality
amygdala	UBERON:0001876	62.09	gold quality
right frontal lobe	UBERON:0002810	61.89	gold quality
jejunal mucosa	UBERON:0000399	61.67	gold quality
caudate nucleus	UBERON:0001873	61.61	gold quality
neocortex	UBERON:0001950	60.05	gold quality
parotid gland	UBERON:0001831	59.72	gold quality
nasal cavity epithelium	UBERON:0005384	59.40	gold quality
frontal cortex	UBERON:0001870	59.05	gold quality
cerebral cortex	UBERON:0000956	57.98	gold quality
hypothalamus	UBERON:0001898	57.69	gold quality
ventricular zone	UBERON:0003053	57.66	silver quality
myocardium	UBERON:0002349	57.35	gold quality
forebrain	UBERON:0001890	56.77	gold quality
primary visual cortex	UBERON:0002436	56.37	gold quality
tendon of biceps brachii	UBERON:0008188	55.88	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	55.54	gold quality
brain	UBERON:0000955	55.40	gold quality
vena cava	UBERON:0004087	55.04	gold quality
seminal vesicle	UBERON:0000998	54.49	gold quality
temporal lobe	UBERON:0001871	54.37	gold quality
spinal cord	UBERON:0002240	54.13	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.14

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 1)

• These results indicate that CACNG4, CACNG5, CACNG6 and CACNG8 may contribute to the risk of SCZ. The statistical epistasis identified between CACNG5 and CACNG6 suggests that there may be an underlying biological interaction between the two genes. (PMID:27102562)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	cacng5a	ENSDARG00000003326
danio_rerio	cacng5b	ENSDARG00000039240
mus_musculus	Cacng5	ENSMUSG00000040373
rattus_norvegicus	Cacng5	ENSRNOG00000003288
drosophila_melanogaster	stg1	FBGN0288700
caenorhabditis_elegans		WBGENE00007670

Paralogs (5): CACNG3 (ENSG00000006116), CACNG4 (ENSG00000075461), CACNG7 (ENSG00000105605), CACNG8 (ENSG00000142408), CACNG2 (ENSG00000166862)

Protein

Protein identifiers

Voltage-dependent calcium channel gamma-5 subunit — Q9UF02 (reviewed: Q9UF02)

Alternative names: Neuronal voltage-gated calcium channel gamma-5 subunit, Transmembrane AMPAR regulatory protein gamma-5

All UniProt accessions (2): Q9UF02, A0A669KBF6

UniProt curated annotations — full annotation on UniProt →

Function. Regulates the gating properties of AMPA-selective glutamate receptors (AMPARs). Modulates their gating properties by accelerating their rates of activation, deactivation and desensitization. Displays subunit-specific AMPA receptor regulation. Shows specificity for GRIA1, GRIA4 and the long isoform of GRIA2. Thought to stabilize the calcium channel in an inactivated (closed) state.

Subunit / interactions. The L-type calcium channel is composed of five subunits: alpha-1, alpha-2/delta, beta and gamma. Acts as an auxiliary subunit for AMPA-selective glutamate receptors (AMPARs). Found in a complex with GRIA1, GRIA2, GRIA3, GRIA4, CNIH2, CNIH3, CACNG2, CACNG3, CACNG4, CACNG7 and CACNG8. Interacts with GRIA1, GRIA2, GRIA3 and GRIA4.

Subcellular location. Membrane. Postsynaptic density membrane.

Similarity. Belongs to the PMP-22/EMP/MP20 family. CACNG subfamily.

RefSeq proteins (2): NP_001358405, NP_665810* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004031	PMP22/EMP/MP20/Claudin	Family
IPR008368	VDCC_gsu	Family
IPR008369	VDCC_g5su	Family
IPR051072	CACNG_subunit	Family

Pfam: PF13903

UniProt features (6 total): transmembrane region 4, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UF02-F1	72.86	0.26

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 105 (showing top): GOBP_POSITIVE_REGULATION_OF_SYNAPTIC_TRANSMISSION_GLUTAMATERGIC, GOBP_REGULATION_OF_SYNAPTIC_TRANSMISSION_GLUTAMATERGIC, KEGG_MAPK_SIGNALING_PATHWAY, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_SYNAPTIC_SIGNALING, GOBP_POSITIVE_REGULATION_OF_SYNAPTIC_TRANSMISSION, GOBP_SYNAPTIC_TRANSMISSION_GLUTAMATERGIC, GOBP_REGULATION_OF_NEUROTRANSMITTER_RECEPTOR_ACTIVITY, GOBP_LOCALIZATION_WITHIN_MEMBRANE, GOBP_REGULATION_OF_TRANSPORT, GOBP_CALCIUM_ION_TRANSMEMBRANE_TRANSPORT, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GOBP_TRANSMEMBRANE_TRANSPORT, KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC

GO Biological Process (7): transmission of nerve impulse (GO:0019226), positive regulation of synaptic transmission, glutamatergic (GO:0051968), postsynaptic neurotransmitter receptor diffusion trapping (GO:0098970), regulation of AMPA receptor activity (GO:2000311), calcium ion transport (GO:0006816), monoatomic ion transmembrane transport (GO:0034220), calcium ion transmembrane transport (GO:0070588)

GO Molecular Function (3): voltage-gated calcium channel activity (GO:0005245), monoatomic ion transmembrane transporter activity (GO:0015075), channel regulator activity (GO:0016247)

GO Cellular Component (8): postsynaptic density (GO:0014069), AMPA glutamate receptor complex (GO:0032281), postsynaptic density membrane (GO:0098839), glutamatergic synapse (GO:0098978), plasma membrane (GO:0005886), membrane (GO:0016020), synapse (GO:0045202), postsynaptic membrane (GO:0045211)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
postsynaptic membrane	2
postsynaptic specialization membrane	2
action potential	1
cell communication	1
chemical synaptic transmission	1
nervous system process	1
synaptic transmission, glutamatergic	1
positive regulation of synaptic transmission	1
regulation of synaptic transmission, glutamatergic	1
receptor localization to synapse	1
regulation of postsynaptic membrane neurotransmitter receptor levels	1
neurotransmitter receptor diffusion trapping	1
AMPA glutamate receptor activity	1
regulation of transmembrane transporter activity	1
regulation of neurotransmitter receptor activity	1
metal ion transport	1
monoatomic ion transport	1
transmembrane transport	1
calcium ion transport	1
monoatomic cation transmembrane transport	1
calcium channel activity	1
voltage-gated monoatomic cation channel activity	1
transmembrane transporter activity	1
monoatomic ion transmembrane transport	1
channel activity	1
transporter regulator activity	1
asymmetric synapse	1
postsynaptic specialization	1
ionotropic glutamate receptor complex	1
postsynaptic density	1
synapse	1
membrane	1
cell periphery	1
cellular anatomical structure	1
cell junction	1
synaptic membrane	1
postsynapse	1

Protein interactions and networks

STRING

1151 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CACNG5	CACNG1	Q06432	916
CACNG5	CACNB1	Q02641	809
CACNG5	CACNA2D1	P54289	705
CACNG5	CACNA1D	Q01668	672
CACNG5	CACNA1B	Q00975	595
CACNG5	GRIA2	P42262	551
CACNG5	PRKCG	P05129	506
CACNG5	PRKCA	P17252	440
CACNG5	CACNG4	Q9UBN1	421
CACNG5	CACNA2D3	Q8IZS8	395
CACNG5	CACNB4	O00305	391
CACNG5	GSG1L	Q6UXU4	360
CACNG5	TRPV2	Q9Y5S1	358
CACNG5	CNIH1	O95406	351
CACNG5	GRIA4	P48058	349

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CACNG5	ZNF316	psi-mi:“MI:0914”(association)	0.530
CACNG5		psi-mi:“MI:0914”(association)	0.350

BioGRID (76): HELZ2 (Affinity Capture-MS), ZNF142 (Affinity Capture-MS), SCAI (Affinity Capture-MS), PLD1 (Affinity Capture-MS), ARHGEF39 (Affinity Capture-MS), MIS18BP1 (Affinity Capture-MS), PRKRIR (Affinity Capture-MS), MBLAC2 (Affinity Capture-MS), MCM10 (Affinity Capture-MS), PLD2 (Affinity Capture-MS), ZC3H3 (Affinity Capture-MS), SGPL1 (Affinity Capture-MS), ZNF865 (Affinity Capture-MS), TTLL5 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS)

ESM2 similar proteins: A0A1D5NY17, A4IF75, B2RVY9, B3SHH9, F6V1J6, O42281, O70578, P19518, P97707, Q06432, Q08CE6, Q08DE1, Q0D289, Q0V9E0, Q14714, Q2MJQ7, Q4R4Z3, Q4V922, Q5CZV0, Q5PRC1, Q5RDV7, Q5XGU1, Q62147, Q66IV3, Q68FV0, Q6AZD1, Q6P0C6, Q6R5J2, Q6ZP80, Q6ZUX7, Q7ZZL8, Q86WI0, Q8BGA2, Q8NBL3, Q8VHW3, Q8VHW4, Q8VHW7, Q8VHW8, Q91Y55, Q925N4

Diamond homologs: O60359, O88602, Q0VD05, Q4R589, Q5R5X2, Q71RJ2, Q8VHW2, Q8VHW4, Q8VHW5, Q8VHW8, Q8VHW9, Q8VHX0, Q8WXS5, Q9JJV4, Q9JJV5, Q9UBN1, Q9UF02, Q9Y698, P62955, P62956, P62957

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	50
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1123 predictions. Top by Δscore:

Variant	Effect	Δscore
17:66835246:GCGAG:G	donor_gain	1.0000
17:66835249:AGG:A	donor_loss	1.0000
17:66835250:GGTAA:G	donor_loss	1.0000
17:66835251:G:GA	donor_loss	1.0000
17:66835252:T:A	donor_loss	1.0000
17:66879059:G:GG	donor_gain	1.0000
17:66880694:TCAGG:T	donor_loss	1.0000
17:66880696:AGGT:A	donor_loss	1.0000
17:66880697:GGTA:G	donor_loss	1.0000
17:66880698:GTAA:G	donor_loss	1.0000
17:66884505:T:A	acceptor_gain	1.0000
17:66884528:T:TA	acceptor_gain	1.0000
17:66884531:T:TA	acceptor_gain	1.0000
17:66884537:T:TA	acceptor_gain	1.0000
17:66884613:G:GG	donor_gain	1.0000
17:66884620:T:TA	donor_gain	1.0000
17:66884621:G:GA	donor_gain	1.0000
17:66884659:G:GT	donor_gain	1.0000
17:66884982:GA:G	acceptor_gain	1.0000
17:66835248:GAG:G	donor_gain	0.9900
17:66835251:G:GG	donor_gain	0.9900
17:66877524:TGCAG:T	donor_loss	0.9900
17:66877526:CAGG:C	donor_loss	0.9900
17:66877527:AGG:A	donor_loss	0.9900
17:66877528:GGTA:G	donor_loss	0.9900
17:66878966:CCACA:C	acceptor_loss	0.9900
17:66878967:CACAG:C	acceptor_loss	0.9900
17:66878968:ACAG:A	acceptor_loss	0.9900
17:66878969:CAG:C	acceptor_loss	0.9900
17:66878970:A:AT	acceptor_loss	0.9900

AlphaMissense

1808 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:66877429:T:A	W33R	0.999
17:66877429:T:C	W33R	0.999
17:66877433:T:C	L34P	0.999
17:66880592:A:C	S107R	0.999
17:66880594:C:A	S107R	0.999
17:66880594:C:G	S107R	0.999
17:66880613:G:A	G114R	0.999
17:66880613:G:C	G114R	0.999
17:66880613:G:T	G114W	0.999
17:66880614:G:A	G114E	0.999
17:66880676:G:C	G135R	0.999
17:66880677:G:A	G135D	0.999
17:66880697:G:C	G142R	0.999
17:66884519:T:C	L143P	0.999
17:66884533:G:C	G148R	0.999
17:66884537:T:C	L149P	0.999
17:66884989:G:A	G193R	0.999
17:66884989:G:C	G193R	0.999
17:66884989:G:T	G193W	0.999
17:66884990:G:A	G193E	0.999
17:66877369:A:C	S13R	0.998
17:66877371:C:A	S13R	0.998
17:66877371:C:G	S13R	0.998
17:66877412:C:A	A27E	0.998
17:66877431:G:C	W33C	0.998
17:66877431:G:T	W33C	0.998
17:66877501:G:C	G57R	0.998
17:66877501:G:T	G57C	0.998
17:66877502:G:A	G57D	0.998
17:66877507:T:A	W59R	0.998

dbSNP variants (sampled 300 via entrez): RS1000064415 (17:66865512 T>C), RS1000090500 (17:66845470 A>AC), RS1000140606 (17:66859547 T>C), RS1000155128 (17:66893648 A>G), RS1000222477 (17:66885524 G>A), RS1000271448 (17:66851431 T>G), RS1000437405 (17:66876966 G>T), RS1000467590 (17:66888585 A>C,G), RS1000558802 (17:66881955 T>C), RS1000633389 (17:66841138 C>T), RS1000649708 (17:66849119 C>T), RS1000670613 (17:66871157 G>T), RS1000731636 (17:66835458 GTGTC>G), RS1000757439 (17:66887307 A>C), RS1000843459 (17:66867097 G>A)

Disease associations

OMIM: gene MIM:606405 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000862_2	Bipolar disorder and schizophrenia	6.000000e-07
GCST003365_6	Systolic blood pressure (cigarette smoking interaction)	2.000000e-06
GCST005944_4	Viral capsid antigen IgG seropositivity	2.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0009272	Epstein Barr viral capsid antigen seropositivity

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2363032 (PROTEIN COMPLEX GROUP)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 67,947 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1428	NIMODIPINE	4	32,587
CHEMBL95	TACRINE	4	35,360

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

58 potent at pChembl≥5 of 75 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.82	IC50	1.5	nM	CHEMBL3891844
8.72	IC50	1.9	nM	CHEMBL3890624
8.62	IC50	2.4	nM	CHEMBL3973392
8.57	IC50	2.7	nM	CHEMBL3891844
8.52	IC50	3	nM	CHEMBL3919024
8.51	IC50	3.1	nM	CHEMBL3919898
8.35	IC50	4.5	nM	CHEMBL3965812
8.23	IC50	5.9	nM	CHEMBL3906126
8.22	IC50	6	nM	CHEMBL3890916
8.15	IC50	7	nM	CHEMBL3940577
8.14	IC50	7.2	nM	CHEMBL3969562
8.12	IC50	7.6	nM	CHEMBL3937280
8.12	IC50	7.6	nM	CHEMBL3965812
8.10	IC50	8	nM	CHEMBL3983323
8.05	IC50	9	nM	CHEMBL3942512
8.03	IC50	9.4	nM	CHEMBL3922498
8.01	IC50	9.7	nM	CHEMBL3897303
7.96	IC50	11	nM	CHEMBL3948329
7.92	IC50	12	nM	CHEMBL3898359
7.85	IC50	14	nM	CHEMBL3911369
7.85	IC50	14	nM	CHEMBL3913505
7.85	IC50	14	nM	CHEMBL3936725
7.82	IC50	15	nM	CHEMBL3984596
7.82	IC50	15	nM	CHEMBL3902376
7.67	IC50	21.5	nM	CHEMBL3952905
7.62	IC50	24	nM	CHEMBL3972896
7.58	IC50	26	nM	CHEMBL3889804
7.55	IC50	28	nM	CHEMBL3958844
7.55	IC50	28	nM	CHEMBL3973382
7.52	IC50	30	nM	CHEMBL3978200
7.52	IC50	30	nM	CHEMBL3985660
7.51	IC50	31	nM	CHEMBL3896861
7.51	IC50	31	nM	CHEMBL3951956
7.50	IC50	31.4	nM	CHEMBL3962403
7.44	IC50	36	nM	CHEMBL3953976
7.44	IC50	36	nM	CHEMBL3925140
7.41	IC50	39	nM	CHEMBL3900691
7.39	IC50	41	nM	CHEMBL3930781
7.30	IC50	50	nM	CHEMBL3921840
7.21	IC50	62	nM	CHEMBL3956991
7.17	IC50	67	nM	CHEMBL3965293
7.09	IC50	81	nM	CHEMBL3958264
7.07	IC50	85	nM	CHEMBL3964411
7.01	IC50	98.5	nM	CHEMBL3953031
6.40	IC50	400	nM	CHEMBL3974355
6.10	IC50	800	nM	CHEMBL3734797
5.75	IC50	1800	nM	CHEMBL4228929
5.66	IC50	2200	nM	CHEMBL4226021
5.52	IC50	3000	nM	CHEMBL4228209
5.52	IC50	3000	nM	CHEMBL4224773

PubChem BioAssay actives

13 with measured affinity, of 101 total; 13 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-tert-butyl-8-[[[(1S,2S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropanecarbonyl]amino]methyl]-5-[3-(trifluoromethoxy)phenyl]-3,4-dihydro-1H-isoquinoline-2-carboxamide	1262825: Inhibition of voltage-gated calcium channel (unknown origin)	ic50	0.8000	uM
5-methyl-1-[(2-nitrophenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	1.8000	uM
1-[(3-chlorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	2.2000	uM
5-methyl-1-[(3-nitrophenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.0000	uM
1-[(4-chlorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.0000	uM
1-benzyl-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.4000	uM
5-methyl-1-[(4-methylphenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.6000	uM
1-[(4-fluorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	4.8000	uM
N-heptyl-16,18-dioxo-17-azapentacyclo[6.6.5.02,7.09,14.015,19]nonadeca-2,4,6,9,11,13-hexaene-1-carboxamide	1612587: Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level after 10 mins by Fluo-4 dye-based fluorescence assay	ic50	9.0000	uM
ethyl 5-amino-4-(3-methoxyphenyl)-2-methyl-7,8,9,10-tetrahydro-6H-cyclohepta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	9.0000	uM
ethyl 5-amino-4-(3,4-dimethoxyphenyl)-2-methyl-7,8,9,10-tetrahydro-6H-cyclohepta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	9.0000	uM
propan-2-yl 5-amino-2-methyl-4-phenyl-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	10.0000	uM
ethyl 5-amino-2-methyl-4-phenyl-6,7,8,9,10,11-hexahydrocycloocta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	10.0000	uM

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, increases methylation	1
cobaltous chloride	affects expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression	1
CGP 52608	affects binding, increases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic Trioxide	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	affects methylation	1
Benzo(a)pyrene	decreases methylation, affects methylation	1
Diethylhexyl Phthalate	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
1-Methyl-4-phenylpyridinium	increases expression	1
Aflatoxin B1	increases methylation	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3737861	Binding	Inhibition of voltage-gated calcium channel (unknown origin)	Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_YA30	IDG-HEK293T-CACNG5-V5-OE	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.